Optimum Perspectives

Great new insights in the Optimum Perspectives' latest podcast edition featuring Stefano Gullà, Chief Scientific Officer at Kling Biotherapeutics, about the growing role of B cell technology in cancer therapy.  

In this podcast to mark Lung Cancer Awareness Month, Optimum’s Richard Staines speaks to Roman Thomas, CEO and founder of Disco Pharmaceuticals, on breakthroughs that have improved patient outcomes, and the company’s efforts to help develop new therapies with its “surfaceome” technology. 

Optimum’s Richard Staines talks to Feride Sahin, Senior Director of Clinical Development at Splice Bio about the importance of World Sight Day, which takes place this week.

It’s time to talk about mushrooms! Or rather the deadly toxin amanitin found in the death cap mushroom, which Heidelberg Pharma is using as a cancer drug with the help of a tumour-targeting antibody, find out more in this episode featuring Heidelberg Pharma's CEO, Andreas Pahl.

Check out Optimum’s latest podcast episode profiling our client Resolution Therapeutics. Lara Campana, VP of Research Operations outlines the company’s technology based around pro-regenerative macrophages and its potential to treat liver disease.

Dr Ruth McKernan CBE is the richly deserved winner of the 2024 Mediscience Award for ‘Most Significant Contribution to the Mediscience Sector’. In this episode Optimum’s Eva Haas discusses the highlights of Ruth’s incredible career, the skills needed for success as a company founder and the heartening advancements in treating neurodegenerative diseases such as Alzheimer's in recent years.

Listen to expert discussion on the role of AI in drug development, featuring Tushar Pandey, CEO and Co-founder of SimBioSys, and Jeremy Skillington, CEO of Poolbeg Pharma.

Southampton-based Curve Therapeutics recently raised a hefty £40m in a Series A financing round. In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”.He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programme – which aims to block two cancer targets called Hypoxia Inducible Factors, or “HIFs”, which enable solid tumours to survive in low-oxygen conditions.Speaking to Optimum’s Stephen Adams, Simon ponders the role of luck in securing investment, both “the kind you deserve because you turn over a lot of stones”, and the more fortuitous variety.

Listen to the latest insights from Gil Bar-Nahum, Managing Director in the Global Healthcare Investment Banking Group, Jefferies International, on how to succeed in the new wave of biotech IPOs in the Optimum Perspectives podcast.